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Introduction
Major depressive disorder (MDD) is a chronic, dis-
abling condition encompassing emotional, behavio-
ural and physical symptoms that impact considerably
upon patients (1,2). Treatment for MDD aims to
achieve complete remission of depressive symptoms
and facilitate a return to normal functioning. Antide-
pressant medications, particularly selective serotonin
reuptake inhibitors (SSRIs) and selective serotonin
and norepinephrine reuptake inhibitors (SNRIs), are
widely used as ﬁrst-line treatment options for MDD.
However, suboptimal response to antidepressant
medication is common; up to 35% of patients trea-
ted in routine clinical practice have an inadequate
response to ﬁrst-line therapy (3) and only a third of
patients may achieve clinical remission criteria (4,5).
Failure to achieve full remission of MDD is associ-
ated with a high risk of chronic symptoms and
impaired quality of life (6–8) and physicians rou-
tinely switch antidepressant medications to improve
clinical response (9). Although switching antidepres-
sant medications is widespread in clinical practice,
systematic evaluations of the consequent efﬁcacy and
tolerability outcomes are limited. Identifying key
response attributes that enhance earlier recognition
of patients who beneﬁt from switching antidepres-
sants would be of value.
Duloxetine hydrochloride (duloxetine) is a rela-
tively balanced dual reuptake inhibitor of serotonin
(5-HT) and norepinephrine (NE) (10,11). In a previ-
ous study, a switch to duloxetine (60–120 mg⁄day)
following SSRI treatment failure produced signiﬁcant
improvements in emotional and physical symptoms
SUMMARY
Background: This study was designed to assess clinical and functional outcomes
associated with switching to duloxetine treatment in patients with major depressive
disorder (MDD) experiencing emotional and painful physical symptoms in their cur-
rent episode. Methods: In this 8-week, multinational, multicentre, single-arm,
open-label clinical trial, 242 MDD patients were switched to duloxetine 60 mg⁄day
after selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine
reuptake inhibitor (SNRI) treatment. The primary analysis compared mean change
from baseline in Brief Pain Inventory – Modiﬁed Short Form (BPI-SF) interference
score between initial responders [‡ 50% reduction from baseline on the 17-item
Hamilton Depression Rating Scale (HAMD17) Maier subscale] and initial non-
responders after 4 weeks. Initial responders continued with duloxetine 60 mg⁄day.
Initial non-responders received duloxetine 120 mg⁄day for the remaining 4 weeks.
Depression, pain, anxiety and functional outcomes were also compared after
8 weeks. Results: BPI-SF interference decreased from baseline in initial responders
(n = 108) and initial non-responders (n = 85) after 4 weeks of duloxetine
treatment, with greater reductions in initial responders [BPI-SF mean difference in
reduction: 1.01 (95% CI 0.42–1.61); p < 0.001]. Reductions in pain interference
favouring initial responders were also apparent after 8 weeks [0.68 (95% CI:
0.03–1.33); p = 0.042]. Depression, pain, anxiety and function improved over
8 weeks across patient groups. Conclusions: Elements of core mood and pain
are important residual symptoms following poor treatment response in MDD. Early
improvement in these symptoms after switching to duloxetine indicated an
increased chance of functional recovery.
What’s known
• Studies have shown that the presence of painful
physical symptoms reduces the likelihood of
remission in depressed patients.
• A relationship between the effective treatment of
painful physical symptoms and depression
remission rates has been recently shown.
• Duloxetine has demonstrated clinical
improvements in painful physical symptoms
associated with major depressive disorder.
What’s new
• This study explores the clinical course and
functional outcomes of depressed patients,
experiencing emotional and painful physical
symptoms, who are switched to duloxetine
treatment.
• The results highlight the importance of
improvements in mood, pain, anxiety and
functioning in the overall remission of patients
with major depressive disorder.
• An early response in these symptoms after
switching to duloxetine may improve the chances
of a clinically meaningful, functional recovery.
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doi: 10.1111/j.1742-1241.2010.02546.x 73of depression, irrespective of whether patients were
switched to duloxetine abruptly or tapered off their
prior SSRI whilst receiving concomitant duloxetine
(9). In addition, duloxetine has demonstrated clinical
improvements in painful physical symptoms (PPS)
associated with MDD (12). Signiﬁcantly greater
reductions in PPS were shown with duloxetine vs.
placebo after 8 weeks of treatment in MDD patients
with at least moderate pain associated with their
major depressive episode (13) and an independent
analgesic effect in MDD has been proposed (14).
The aim of this current study was to focus on the
attributes of response in MDD patients with at least
moderate pain, further expanding on the available
data on switching to duloxetine following partial or
non-response to SSRIs.
The primary objective of this study was to investi-
gate the change in pain interference [as represented
by the Brief Pain Inventory – Modiﬁed Short Form
(BPI-SF) interference score], relative to a change in
core mood symptoms [as represented by the Maier
subscale of the 17-item Hamilton Depression Rating
Scale (HAMD17)]. The core emotional symptoms of
depression represented by the HAMD17 Maier sub-
scale include depressed mood, feelings of guilt, loss of
interest in work and daily activities, psychomotor
retardation, agitation and psychic anxiety (15). With
the relatively balanced dual mechanism of action of
duloxetine (16), it was hypothesised that patients who
demonstrated improvements on the Maier subscale
initially would show a higher degree of improvement
in pain interference than patients who did not (1).
Methods
Study design
This multicentre, single-arm, open-label trial evalu-
ated duloxetine in outpatients with MDD who failed
to respond to one course of treatment with either an
SSRI or SNRI antidepressant for the current depres-
sive episode (at study entry).
Patients who met the study eligibility criteria were
treated with open-label duloxetine, 60 mg⁄day, for
4 weeks (acute therapy period), after which they
entered a further 4-week treatment period. Patients
who did not initially respond on the Maier subscale
during the acute therapy period received duloxetine
120 mg⁄day (dose-optimisation period) for an addi-
tional 4 weeks, whereas responding patients main-
tained the 60 mg⁄day dose. In accordance with the
principles of the Declaration of Helsinki, all patients
provided informed consent prior to the administra-
tion of any study drug.
Based on a previous duloxetine study, the propor-
tion of patients demonstrating a Maier response
when switched from an SSRI or SNRI to duloxetine
for 4 weeks was estimated to be 44% and 22%,
respectively (9). The estimated ratio of SSRI⁄SNRI
patients entering this study was 60 : 40, with the
overall response estimated at 35%.
Using data from another duloxetine study (17),
the mean (SD) difference in BPI-SF interference
score between initial responders and initial non-
responders in the acute therapy phase was estimated
to be )1.64 (2.8). Approximately 240 patients with a
25% dropout rate was calculated to provide 90%
power at a response rate of 25% and provide 96%
power for a response rate of 35%.
Selection of patients
Study participants were outpatients from 22 sites in
Brazil, Canada, China and Korea, aged 18 years or
older, who met the Diagnostic and Statistical Manual
for Mental Disorders, 4th Edition, Text Revision
(DSM-IV-TR) (18) disease diagnostic criteria for
MDD. Patients were receiving either an SSRI or
SNRI antidepressant prescribed for depression treat-
ment at locally recommended doses, for at least
4 weeks prior to study entry. A HAMD17 score ‡ 15
(19), Clinical Global Impression of Severity (CGI-S)
score ‡ 3 and BPI-SF interference score ‡ 3 were
required at screening and baseline.
Patients were ineligible to participate if they met
any of the following criteria: a current primary Axis
I disorder other than MDD; a history of substance
abuse or dependence; any organic pain syndrome or
continuous analgesic use for chronic pain; pregnancy
or breastfeeding; and previous failure with duloxetine
treatment or treatment-resistant depression (20).
Patients who were at suicidal risk, or had a serious
medical condition likely to require hospitalisation
and⁄or use of excluded medications were also
excluded.
Treatments administered
Patients received duloxetine 60 mg⁄day, adminis-
tered orally with food following a direct switch
from an SSRI or SNRI antidepressant (with the
exception of ﬂuoxetine, which had to be discontin-
ued for a minimum of 28 days prior to baseline).
After 4 weeks, patients who responded to duloxe-
tine (‡ 50% reduction from baseline on the Maier
subscale of the HAMD17; ‘initial responders, IR’)
continued to receive 60 mg⁄day for the remaining
4 weeks. Patients who did not respond to duloxe-
tine in this initial 4-week period (< 50% reduction
from baseline on the Maier subscale of the
HAMD17; ‘initial non-responders, INR’) received
duloxetine 120 mg⁄day for the remainder of the
study.
Clinical Trial Registry
Information
The results of this study
(F1J-CR-S022) are available on
clinicaltrials.gov under the
identiﬁer #NCT00696774.
Re-use of this article is
permitted in accordance with
the Terms and Conditions set
out at http://wileyonlinelibrary.
com/onlineopen#OnlineOpen_
Terms
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study were recorded. Patients were excluded from
taking any antidepressant other than duloxetine.
Patients requiring continuous use of analgesics
(>Step 2 of the WHO deﬁnition) because of chronic
pain for greater than 6 months were excluded from
the study. Episodic use of some analgesics, non-
steroidal anti-inﬂammatory drugs (NSAIDs) and nar-
cotics was allowed if used to treat acute injury or
surgical procedure for no longer than six consecutive
days.
Clinical and functional outcomes and safety
evaluations
The primary objective of this study was to compare
the mean change in BPI-SF interference score from
baseline to week 4 between the IR and INR groups.
A secondary focus was the BPI-SF interference score
in responders and non-responders at week 8. The
terms ‘responders’ and ‘non-responders’ were used
to describe the 8-week secondary outcomes of the IR
and INR groups.
Other secondary measures were: longitudinal
assessments of mean baseline to week 8 change in
HAMD17 total score and Maier subscales; the Hamil-
ton Anxiety Rating Scale (HAM-A) total score and
subscales; the BPI-SF average pain score; the CGI-S
score; the Patient Global Impression of Improvement
(PGI-I) score; and the Sheehan Disability Scale
(SDS).
The proportion of patients achieving HAMD17
Maier response (‡ 50% reduction from baseline);
HAMD17 Maier onset (‡ 20% improvement from
baseline); HAMD17 Maier sustained response (Maier
response sustained through the end of the study);
HAMD17 total response (‡ 50% reduction from
baseline) and sustained response (total response sus-
tained through the end of the study); HAMD17 total
remission (total score £ 7) and sustained remission
(total score £ 7 sustained through the end of the
study); BPI-SF interference onset score (‡ 30%
improvement); BPI-SF interference score with ‡ 50%
improvement, at 4 weeks and 8 weeks; and the time
to onset of these criteria were also assessed.
Dose-optimisation in the INR group was assessed
using HAMD17 Maier subscore and HAMD17 total
score response rates, as well as the HAMD17 remis-
sion rate.
All adverse events were reported during the study
period using spontaneously reported treatment-
emergent adverse events (TEAEs), discontinuations
due to adverse events (AEs) and vital signs. Safety
measures included physical examination, blood
pressure and heart rate, pre-existing conditions and
concomitant medications. Laboratory measurements
included haematology, chemistry and electrolytes, uri-
nalysis, urine pregnancy test and urine drug screen.
The measures used in this study have been docu-
mented and validated in the literature and are gener-
ally regarded as reliable and relevant tools for the
assessment of MDD patients. All study investigators
were trained in the proper administration of each
scale.
All screened
N = 270
All enrolled
n = 242 (89.6%)
Completed week 4
n = 206 (85.1%)
Discontinued before
enrollment, n = 2 (0.7%)
Screen failure
n = 26 (9.6%)
Discontinued before
week 4, n = 36 (14.9%)
Initial non-responder
n = 91 (44.2%)
Initial responder
n = 115 (55.8%)
Discontinued before
week 8, n = 9 (7.8%)
Completed week 8
(responder)
n = 106 (92.2%)
Discontinued before
week 8, n = 10 (11.0%)
Completed week 8
(non-responder)
n = 81 (89.0%)
Figure 1 Patient disposition
Table 1 Patient baseline demographics
Characteristic IR (n = 115) INR (n = 91) Overall* (N = 242)
Mean age, years (SD) 43.5 (12.9) 45.6 (12.5) 44.9 (12.5)
Female, n (%) 88 (76.5) 64 (70.3) 182 (75.2)
Country
Brazil, n (%) 9 (7.8) 11 (12.1) 33 (13.6)
Korea, n (%) 18 (15.7) 11 (12.1) 38 (15.7)
China, n (%) 25 (21.7) 13 (14.3) 41 (16.9)
Canada, n (%) 63 (54.8) 56 (61.5) 130 (53.7)
Previous treatment
SSRI, n (%) 83 (72.8) 69 (76.7) 177 (74.4)
SNRI, n (%) 31 (27.2) 21 (23.3) 61 (25.6)
Last previous SNRI⁄SSRI antidepressant
Citalopram, n (%) 22 (19.3) 15 (16.7) 41 (17.2)
Escitalopram, n (%) 16 (14.0) 15 (16.7) 32 (13.4)
Fluoxetine, n (%) 3 (2.6) 4 (4.4) 9 (3.8)
Paroxetine, n (%) 29 (25.4) 21 (23.3) 61 (25.6)
Sertraline, n (%) 13 (11.4) 14 (15.6) 34 (14.3)
Venlafaxine, n (%) 31 (27.2) 21 (23.3) 61 (25.6)
*Overall data include patients with ‘unclassiﬁed’ response – these were the patients who
discontinued before week 4 and therefore did not have a primary outcome measure
(n = 36). IR, initial responders; INR, initial non-responders; SSRI, selective serotonin reuptake
inhibitor; SNRI, serotonin norepinephrine reuptake inhibitor.
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Data of all enrolled patients were included in the sta-
tistical analyses. All patients who received at least
one dose of study drug were included in the safety
analyses. Patients with signiﬁcant protocol violations
or non-compliance were excluded from the outcomes
analyses. Patients who received incorrect dose-
optimisation at week 4 were included in outcomes
analyses up to the time of dose-optimisation.
Comparisons between initial responders and initial
non-responders, as classiﬁed at week 4, were made
for most of the outcomes analyses.
Two-sided signiﬁcance levels of 0.05 and 0.10 were
deﬁned a priori to evaluate group- and interaction-
effects, respectively. No formal adjustments were
made for multiple comparisons. No imputations
were conducted for missing covariates. Descriptive
statistics were used to characterise patients at study
entry. A two-sample t-test was used to compare con-
tinuous variables and Fisher’s exact test for categori-
cal variables. Covariate adjustment, including
prespeciﬁed known potential confounders as ﬁxed,
categorical effects of gender, group (IR, INR and
responders, non-responders), country, visit number,
previous therapy (SSRI⁄SNRI), reason for switch,
response group-by-visit interaction, response group-
by-country interaction, as well as continuous covari-
ates of age and baseline score, were made to control
for baseline imbalances for all adjusted mixed effects
model for repeated measures (MMRM) longitudinal
analyses. All postbaseline cross-sectional analyses
were adjusted for age, gender, baseline score,
response group, country and response group-
by-country interaction. Statistical analyses were
performed using sas
  for Windows, version 9.1.3
(SAS Institute Inc., Cary, NC).
Outcome-related changes from baseline were
analysed longitudinally up to week 8 using a
MMRM approach. Within-patient errors were mod-
elled using the unstructured covariance matrix, and
the Kenward–Rodger method was used to estimate
the denominator degrees of freedom for ﬁxed
effects. A type III sum-of-squares was used for the
least-squares means. Longitudinal change in PGI-I
was assessed using baseline CGI-S as a proxy con-
trol for baseline severity in the PGI-I MMRM
model.
A MMRM sensitivity analysis using all enrolled
patients was conducted for the primary outcome and
a cross-sectional analysis of covariance (ANCOVA)
was conducted at weeks 4 and 8 as a sensitivity anal-
ysis for all outcome measures.
Percentages and 95% conﬁdence intervals (CIs) for
patients meeting criteria for all onset, response, sus-
tained response, remission and sustained remission
measures at week 4 and 8 were reported. Maier
response, HAMD17 overall response and HAMD17
sustained remission for non-responders were analy-
sed at week 8.
The median time to onset of the indicator vari-
ables, with 95% CIs for the overall patient popula-
tion, was obtained using the Kaplan–Meier method.
Time to BPI-SF interference onset between IR and
INR was compared using the log-rank test. Cross-
sectional analyses at week 4 and 8 were conducted
using an ANCOVA model to assess changes in vital
signs from baseline to week 8.
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Figure 2 Change in BPI-SF interference score from baseline to week 8 (adjusted
MMRM analysis). Overall mean difference in BPI-SF in initial responders vs. initial
non-responders at week 4: 1.01 (95% CI: 0.42–1.61); p < 0.001, and responders vs.
non-responders at week 8: 0.68 (95% CI: 0.03–1.33); p = 0.042. BPI-SF, Brief Pain
Inventory – Modiﬁed Short Form
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Figure 3 Mean change in HAMD17 Maier subscale score from baseline to week 8
(adjusted MMRM analysis). Mean difference in HAMD17 Maier score between
responders and non-responders at week 8: 3.29 (95% CI: 4.10, 2.48); p < 0.001
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Patient disposition
Of the 242 patients enrolled in the 4-week acute
therapy phase, 206 completed this initial treatment
period. Of these, 115 (55.8%) patients were classiﬁed
as IR and continued receiving duloxetine 60 mg⁄day,
whereas 91 (44.2%) were classiﬁed as INR and
received duloxetine 120 mg⁄day for an additional
4 weeks; 92.2% of the IR group (‘responders’) and
89.0% of the INR group (‘non-responders’) com-
pleted the 8-week study. Thirty-six patients discon-
tinued the study before week 4 and did not record a
primary outcome measure; these patients were
‘unclassiﬁed’. Figure 1 illustrates the patient disposi-
tion during the study. Seven IR and six INR patients
were excluded from outcome analyses because of
signiﬁcant protocol violation or non-compliance. A
further two IR and four INR patients were excluded
from outcome analyses beyond week 4 caused by
inadequate dose-optimisation.
Baseline demographics
A majority of patients were women (75.2%), with a
mean age of 44.9 years (Table 1). Most patients were
enrolled from Canada (53.7%), with China, Korea
and Brazil contributing 16.9%, 15.7% and 13.6% of
patients, respectively. The most frequently prescribed
previous treatments were SSRIs (177⁄206; 74.4%).
Paroxetine and venlafaxine were the most commonly
prescribed previous SSRI and SNRI treatments,
respectively. Baseline characteristics were similar
between IR and INR groups (Table 1).
Primary and secondary outcome analyses
The mean reduction in BPI-SF interference at week 4
was greater in IRs than INRs [BPI-SF mean differ-
ence of reduction: 1.01 (95% CI, 1.61–0.42);
p < 0.001]. At week 8, the difference of mean reduc-
tion from baseline BPI-SF interference between
responders and non-responders was 0.68 (95% CI,
0.03–1.33; p = 0.042) (Figure 2).
Reductions in HAMD17 Maier subscale scores
from baseline to week 8 were greater in responders
than in non-responders (Figure 3). The mean differ-
ence in reduction between responders and non-
responders at week 8 was 3.29 (95% CI, 4.10–2.48;
p < 0.001) for HAMD17 Maier scores and 5.85 for
HAMD17 total scores (95% CI, 7.34–4.36; p < 0.001)
(Figure 4).
Responders also showed greater improvements in
anxiety symptoms from baseline than non-respond-
ers [mean difference in reduction in HAM-A total
score at week 8: 4.42 (95% CI, 6.04–2.80; p < 0.001);
Figure 5]. Country and previous SSRI⁄SNRI were
found to have no statistically signiﬁcant effect on the
change from baseline to week 8 in BPI-SF interfer-
ence, HAMD17 Maier subscale score, HAMD17 total
score or HAM-A total score.
Table 2 summarises the change from baseline to
week 4 and week 8 for primary and secondary out-
come measures. In general, patients were moderately
ill at baseline and disease severity improved over
8 weeks, with a higher degree of improvement shown
by IR and all responders (mean change in CGI-S at
4 weeks: 1.94 in IR vs. 0.57 in INR, p < 0.001; at
8 weeks: 2.52 in responders vs. 1.40 in non-respond-
ers, p < 0.001). This was also reﬂected by PGI-I
scores over 8 weeks in all patient groups (Table 2).
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Figure 4 Mean change in HAMD17 total score from baseline to week 8 (adjusted
MMRM analysis). Mean difference in HAMD17 total score between responders and
non-responders at week 8: 5.85 (95% CI: 7.34, 4.36); p < 0.001. HAMD17, 17-item
Hamilton Depression Rating Scale
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Figure 5 Change in HAM-A total score from baseline to week 8 (adjusted MMRM
analysis). Mean difference in HAM-A total score between responders and non-
responders at 8 weeks: 4.42 (95% CI: 6.04, 2.80); p < 0.001. HAM-A, Hamilton
Anxiety Rating Scale
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all patient groups (Table 2).
The majority of patients (93.3%) reported Maier
onset (‡ 20% improvement) by week 8, and 68.7%
and 53.0% of patients achieved HAMD17 response
and sustained response, respectively. Over two-thirds
of all patients achieved ‡ 50% improvement in
BPI-SF interference and HAMD17 remission was
achieved by 46.4% of patients at week 8 (Table 3).
The BPI-SF interference onset (‡ 30% improvement)
and response (‡ 50% improvement) was achieved
more quickly in responders than non-responders
(Log-rank test results: onset, 14 days vs. 20 days,
p = 0.008; response: 21 days vs. 42 days, p < 0.001).
Following duloxetine dose-optimisation to
120 mg⁄day, 51.3% and 44.7% of INR achieved
Maier response and HAMD17 total response at week
8, respectively.
Safety and tolerability
Table 4 summarises the AEs reported during the
study. Overall, 153 patients (63.5%) reported TEAEs
and two patients (both non-responders) experienced
serious AEs during the study. One of these patients
experienced worsening MDD symptoms and discon-
tinued, the other patient experienced severe dermati-
tis. Eighteen patients overall [one patient (0.9%) in
the responder group, two patients (2.2%) in the
non-responder group and 15 ‘unclassiﬁed’ patients]
discontinued the study as a result of AEs; no deaths
were reported. The most common AEs reported
included nausea, headache, dry mouth, dizziness,
constipation, insomnia, somnolence and fatigue.
There were no clinically important changes from
baseline in vital signs of heart rate, blood pressure
and body mass index at weeks 4 and 8 and no statis-
tically signiﬁcant differences between responders and
non-responders were observed.
Discussion
In this open-label, multicentre study, switching treat-
ment to duloxetine 60 mg⁄day produced greater,
clinically meaningful, improvements in interference
associated with painful physical symptoms in MDD
patients whose core mood symptoms improved at
4 weeks (‡ 50% improvement in HAMD17 Maier
subscale score) compared with those whose mood
did not improve. This provides an insight into the
response timeline and the association between spe-
ciﬁc depressive symptoms upon switching antide-
pressant treatment.
Residual symptoms of MDD are often physical,
including pain, and can be strong predictors of
relapse (21). Patients, as in this study, may also
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unsuccessful SSRI⁄SNRI treatment (2). In this ethni-
cally and culturally diverse study, patients were
included based on the presence of painful physical
symptoms of at least moderate intensity (mean base-
line BPI-SF average pain score: 4.8), having received
treatment with SSRIs⁄SNRIs for at least 4 weeks for
their current episode. Improvements in pain inter-
ference were observed with duloxetine at weeks 4
and 8 in most patients, with a higher degree of
improvement in patients showing early signiﬁcant
improvements in mood. The onset of pain relief was
rapid, particularly in the IR group. The median time
to BPI-SF interference onset was 14 days in these
patients, compared with 20 days in the INR group,
suggesting a possible association between rapid pain
reduction and improvements in core depressive
symptoms. The present ﬁndings align with a previ-
ous assessment of time course of depression symp-
tom improvement for duloxetine vs. placebo, where
clinically meaningful symptomatic improvement was
detected after 2 weeks. In that study, response was
quickest on items assessing speciﬁc pain, mood,
guilt, anxiety, suicidal ideation and work activities
that are thought to comprise the core emotional
symptoms of depression and suggested that early
improvement in select symptoms may be an important
indicator of long-term symptomatic resolution (22).
It has been postulated that the dual reuptake
mechanism of action of duloxetine targets both the
emotional and the physical symptoms of depression
(1,23). The present ﬁndings suggest that the rapid
and clinically signiﬁcant improvement in pain shown
by MDD patients switched to duloxetine is also
accompanied by rapid and signiﬁcant improvement
in HAMD17 total and Maier subscore response and
HAMD17 remission over 8 weeks, most notably in
the IR group. Furthermore, signiﬁcant improvements
in HAM-A total score and pain interference from
baseline in the responder group align with previous
placebo-controlled studies demonstrating the beneﬁts
of duloxetine in treating anxiety symptoms of MDD
and generalised anxiety disorder (GAD) and the PPS
accompanying GAD (24,25).
Studies have shown that PPS reduces the likeli-
hood of MDD remission (26), and a relationship
between the effective treatment of pain symptoms
and high HAMD17 remission rates was recently dem-
onstrated (27). There is also evidence to suggest that
noradrenergic or mixed reuptake inhibitor antide-
pressants may be more effective at relieving PPS than
SSRIs (26). The presence and severity of PPS in
MDD patients may therefore be an indicator of ini-
tial poor outcome following treatment with an SSRI.
Addressing PPS while treating the core emotional
symptoms in these patients may facilitate remission
and functional improvements.
The most frequently reported TEAEs (and their
prevalence) in this study were consistent with those
observed in previous open-label and placebo-con-
trolled studies of duloxetine, notably: nausea, head-
ache, dry mouth, dizziness and constipation (28,29).
Table 3 Proportion of patients achieving secondary outcome measures at weeks 4
and 8
Variable (N = 193)
Proportion of patients
achieving outcome
[n (%)] Time to event
[median days
(95% CI)] Week 4 Week 8
HAMD17 Maier
Onset (‡ 20% improvement) 166 (86.0) 167 (93.3) 12 (8–14)
Response (‡ 50% improvement) 108 (56.0) 132 (73.7) 22 (21–28)
Sustained response 85 (44.0) 109 (60.2) 42 (30–44)
HAMD17 Total
Response (‡ 50% improvement) 88 (45.6) 123 (68.7) 28 (23–30)
Sustained response 70 (36.3) 96 (53.0) 44 (n⁄a)
Remission (£ 7) 54 (28.0) 83 (46.4) 56 (43–58)
Sustained remission 42 (21.8) 63 (34.8) 41 (29–43)
BPI-SF interference
Onset (‡ 30% improvement) 124 (64.2) 140 (78.2) 14 (14–16)
Response (‡ 50% improvement) 98 (50.8) 120 (67.0) 21 (21–26)
Percentages are based on number reporting. Patients must have continued to meet the
relevant criterion throughout the remainder of the study. BPI-SF, Brief Pain Inventory – Modi-
ﬁed Short Form; CI, conﬁdence interval; HAMD17, 17-item Hamilton Depression Rating Scale;
n⁄a, not applicable.
Table 4 Summary of adverse events in ‡ 5% of overall patients
Event
Responders
(n = 115)
Non-responders
(n = 91)
Overall*
(n = 241)
Treatment-emergent AEs, n (%) 71 (61.7) 60 (65.9) 153 (63.5)
Discontinuations because of AEs, n (%) 1 (0.9) 2 (2.2) 18 (7.5)
Serious AEs, n (%) 0 (0.0) 2 (2.2) 2 (1.0)
Most common AEs (‡ 5%), n (%)
Nausea 20 (17.4) 15 (16.5) 35 (17.0)
Headache 15 (13.0) 15 (16.5) 30 (14.6)
Dry mouth 12 (10.4) 14 (15.4) 26 (12.6)
Dizziness 15 (13.0) 10 (11.0) 25 (12.1)
Constipation 13 (11.3) 9 (9.9) 22 (10.7)
Insomnia 10 (8.7) 10 (11.0) 20 (9.7)
Somnolence 8 (7.0) 7 (7.7) 15 (7.3)
Fatigue 3 (2.6) 7 (7.7) 13 (5.4)
*Overall data include patients with ‘unclassiﬁed’ response – these were patients who discon-
tinued before week 4 and therefore did not have a primary outcome measure (n = 36). AE,
adverse event.
Depressed patients switched to duloxetine 79
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patients overall discontinued the study as a result of
AEs (15 of these patients did not report a primary
outcome measure). In a previous switch study of
duloxetine, lower study discontinuations were
reported by patients who switched treatment from a
previous SSRI antidepressant compared to patients
who had not been receiving treatment prior to dul-
oxetine (30). Prior use of an SSRI⁄SNRI antidepres-
sant has been suggested to act as a ‘buffer’ against
AEs associated with subsequent treatment using dif-
ferent antidepressants of the same class (9), which
may account for the lower rate of TEAE-related dis-
continuations with duloxetine in patients who
recorded a primary outcome measure.
There are several limitations that warrant consid-
eration when interpreting the results of this study.
Firstly, this was an open-label, single-arm study with
no comparator arm. Consequently, the data pre-
sented here may be limited by the biases inherent in
open-label studies. In addition, the single-arm study
design meant that a path analysis to identify the spe-
ciﬁc domains that contributed to the observed
improvements in mood, anxiety, pain and function
was not possible. Further exploration of the relation-
ship between the individual components of depres-
sion and how these contributed to patient
improvement in this study is required. Secondly,
there was no duloxetine 60 mg⁄day treatment arm in
the non-responder group during dose-optimisation;
therefore, comparisons cannot be made with patients
receiving duloxetine 120 mg⁄day who were late
responders. Similarly, there was no dose-optimisation
of the IR group, who may have experienced further
treatment effects with a higher dose despite an early
response. The lack of comparison with another anti-
depressant medication also limits the conclusions
that can be drawn about the clinical outcomes with
duloxetine following switching from previous
SSRI⁄SNRI antidepressant treatments.
A wider degree of divergence in the secondary out-
come analyses was observed between the IR and INR
groups at week 4 compared with weeks 1–3 of this
study. It is possible that this wider divergence was
related to a more refractory patient population that
improved after a further 4 weeks of dose-optimisa-
tion (late responders). This observation will be con-
sidered in a future paper, one that will also aim to
understand related functional improvements and
more speciﬁc attributes of response.
Conclusion
In patients switched from SSRIs⁄SNRIs to duloxetine
60 mg⁄day for 4 weeks, initial responders on the
Maier subscale showed greater improvement in pain
interference than initial non-responders did. These
signiﬁcant responder⁄non-responder differences also
extended to improvements in overall depressive
response and remission, anxiety and functional out-
come measures. Elements of core mood and pain are
important residual symptoms of MDD; an early
response in these symptoms after switching to
duloxetine improved the chances of a clinically
meaningful functional recovery.
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